Immunomodulation: checkpoint blockade etc

William T. Curry, Michael Lim

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


The immune microenvironment is considered a major obstacle to generating an effective antitumor immune response. Checkpoint inhibitors manipulate the co-stimulatory response between antigen-presenting cells and immune cells-or between the tumor and immune cells-to elicit an antitumor immune response that would have otherwise been suppressed. Checkpoint inhibitors have shown great promise in the clinics, and some inhibitors such as anti-CTLA-4 antibodies and anti-PD-1 antibodies have gained FDA approval for certain tumors. Here we will discuss the current state of checkpoint inhibitors, biomarker strategies, and management of associated toxicities in glioblastoma.

Original languageEnglish (US)
Pages (from-to)vii26-vii31
StatePublished - Nov 1 2015


  • biomarker
  • checkpoint blockade
  • clinical trial
  • glioblastoma
  • immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research


Dive into the research topics of 'Immunomodulation: checkpoint blockade etc'. Together they form a unique fingerprint.

Cite this